Document is current
Any future updates will be listed below
-
Authors
Hall, Andrew G.
Burek, Dominika J. https://orcid.org/0000-0001-8046-5104
Hisey, Erin E.
Seabrook, Lauren T.
Fritsch, Emma L.
Foilb, Allison R.
Beatty, Zoe G.
Ressler, Kerry J. https://orcid.org/0000-0002-5158-1103
Kangas, Brian D. https://orcid.org/0000-0002-4597-9801
Carlezon Jr, William A. https://orcid.org/0000-0002-4162-3947
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH063266, T32MH125786)
Tommy Fuss Fund
Rappaport Foundation
- License Information
-
More Information
Article History
Received: 18 April 2025
Revised: 24 July 2025
Accepted: 27 August 2025
First Online: 6 October 2025
Competing interests
: Within the last 3 years, WAC has served as a Consultant for AbbVie, Neumora, and Psy Therapeutics, and has Sponsored Research Agreements from AbbVie and Delix. KJR has served as a consultant for Acer, Bionomics, Bioxcel, and Jazz Pharma; serves on Scientific Advisory Boards for Boehringer Ingelheim, Sage, and Senseye; and has received prior sponsored research support from Alto Neuroscience. BDK has had sponsored research agreements with BlackThorn Therapeutics, Compass Pathways, Delix Therapeutics, Engrail Therapeutics, Neurocrine Biosciences, and Takeda Pharmaceuticals. No funding from any of these entities was used to support the current work. None of the other authors report conflicts of interest or relevant disclosures.
: All experimental procedures were approved by the Institutional Animal Care and Use Committee at McLean Hospital and were performed in accordance with the National Institutes of Health’s (NIH) Guide for the Care and Use of Animals.
